However, the most recent ASCO guideline on GGT panels in patients with cancer proposes that when GGT is indicated for a patient with cancer, multigene panel testing should be offered if more than one gene is relevant, including BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, and TP53 genes (31). The gene discussed is PALB2; the disease is cancer.